DK1377667T3 - Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme - Google Patents

Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme

Info

Publication number
DK1377667T3
DK1377667T3 DK02714638T DK02714638T DK1377667T3 DK 1377667 T3 DK1377667 T3 DK 1377667T3 DK 02714638 T DK02714638 T DK 02714638T DK 02714638 T DK02714638 T DK 02714638T DK 1377667 T3 DK1377667 T3 DK 1377667T3
Authority
DK
Denmark
Prior art keywords
cancer
fusion proteins
autoimmune diseases
specific treatment
novel therapeutic
Prior art date
Application number
DK02714638T
Other languages
English (en)
Inventor
Mathieu Hubertus Maria Noteborn
Ying-Hui Zhang
Johan Renes
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Application granted granted Critical
Publication of DK1377667T3 publication Critical patent/DK1377667T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK02714638T 2001-03-30 2002-03-28 Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme DK1377667T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28022901P 2001-03-30 2001-03-30
PCT/NL2002/000204 WO2002079222A2 (en) 2001-03-30 2002-03-28 Fusion proteins for specific treatment of cancer and auto-immune diseases

Publications (1)

Publication Number Publication Date
DK1377667T3 true DK1377667T3 (da) 2009-03-30

Family

ID=23072205

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02714638T DK1377667T3 (da) 2001-03-30 2002-03-28 Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme

Country Status (9)

Country Link
US (1) US20020176860A1 (da)
EP (1) EP1377667B1 (da)
AT (1) ATE414776T1 (da)
AU (1) AU2002246455A1 (da)
DE (1) DE60229924D1 (da)
DK (1) DK1377667T3 (da)
ES (1) ES2321485T3 (da)
PT (1) PT1377667E (da)
WO (1) WO2002079222A2 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101921820B (zh) * 2010-02-10 2013-03-27 赵洪礼 具有活性重组肿瘤特异性凋亡因子的制备方法及其制品的应用
CN101875688B (zh) * 2010-02-10 2013-04-17 赵洪礼 重组肿瘤特异性凋亡因子制备方法中的叶酸化修饰步骤及其制品的应用
WO2012091563A1 (en) 2010-12-27 2012-07-05 Apo-T B.V. A polypeptide that binds aberrant cells and induces apoptosis
JP2014530009A (ja) 2011-09-29 2014-11-17 エーピーオー‐ティー ビー．ヴイ． 異常細胞を標的とする多重特異性結合分子
CA2860914A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188832A1 (en) * 2000-09-08 2002-03-20 Leadd B.V. A delivery method for the tumor specific apoptosis inducing activity of apoptin
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
ATE241808T1 (de) * 1995-06-07 2003-06-15 Leadd Bv Verwendungen von apoptin
KR20010022812A (ko) * 1997-08-12 2001-03-26 리드 비.브이. 인자의 변형능력을 측정하는 방법
DE60003632T2 (de) * 1999-01-11 2004-04-15 Leadd B.V. Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1186665A1 (en) * 2000-09-08 2002-03-13 Leadd B.V. A delivery method for the tumor specific apoptosis inducing activity of apoptin
AU2002259005A1 (en) * 2001-04-24 2002-11-05 Washington University Compositions and methods for inducing cancer cell death

Also Published As

Publication number Publication date
WO2002079222A3 (en) 2003-05-08
EP1377667B1 (en) 2008-11-19
US20020176860A1 (en) 2002-11-28
ES2321485T3 (es) 2009-06-08
PT1377667E (pt) 2009-03-13
WO2002079222A2 (en) 2002-10-10
EP1377667A2 (en) 2004-01-07
DE60229924D1 (de) 2009-01-02
ATE414776T1 (de) 2008-12-15
AU2002246455A1 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
EP1194164B8 (en) Prion protein peptides and uses thereof
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
BR0209254A (pt) anticorpos de bloqueio cripto e usos dos mesmos
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
BR0212256A (pt) Proteìnas de fusão de transferrina modificadas
EP1408986A4 (en) PROTEOMIMETIC COMPOUNDS AND CORRESPONDING METHODS
BR0214650A (pt) Imunocitoquinas com seletividade modulada
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
CY1105895T1 (el) Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης
BRPI0413449A (pt) compostos de quinoxalina
DE60039752D1 (de) Herstellung tetravalenter antikörper
EA200500218A1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
NO20055838L (no) Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
MX2023004595A (es) Proteinas de fusion interleucina-2-fc y metodos de uso.
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
DK1097173T3 (da) Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler
DE60204224D1 (de) Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
DK1377667T3 (da) Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme
DK1465927T3 (da) BAG3-antistoffer til anvendelse til forskning, diagnostik og behandling af sygdomme, der omfatter celledød
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.